Why aerosol performance must be part of stability testing:

Inhalation products such as pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizer solutions are highly dependent on device functionality and aerosol characteristics. The therapeutic effect is governed by the accurate delivery of a defined particle size to the lungs. Over time, physical or chemical changes in the formulation, valve integrity, or propellant loss can affect aerosol behavior. Including aerosol performance in your stability protocol ensures the inhaler’s clinical performance remains within specifications over time.

What can go wrong without performance testing:

Failure to monitor aerosol properties during stability may result in:

• Inaccurate delivered dose (DDU)
• Shift in fine particle fraction (FPF) or mass median aerodynamic diameter (MMAD)
• Loss of actuator spray pattern or plume geometry
• Device malfunction under high or low humidity conditions

These issues directly affect the product’s bioavailability and safety, especially in critical care settings like asthma, COPD, or cystic fibrosis treatment.

Regulatory and Technical Context:

Guidelines for inhalation stability from ICH and WHO:

ICH Q1A(R2) and WHO TRS 1010 mandate stability testing of inhalation products under conditions simulating long-term and accelerated storage. For orally inhaled and nasal drug products (OINDPs), regulatory agencies such as the US FDA, EMA, and MHRA expect inclusion of device-drug combination performance metrics. The CTD Module 3.2.P.8.3 must include data demonstrating consistent delivered dose and aerodynamic profile throughout the claimed shelf life.

Regulatory audit and filing expectations:

Auditors often request aerosol performance data across time points, especially if post-marketing complaints involve dose delivery issues or device failure. Missing or inconsistent data may trigger product recalls, shelf life reduction, or regulatory delays. Agencies expect validated methods for DDU and APSD (e.g., using NGI or Andersen cascade impactors), with trend analysis that confirms dose and particle size reproducibility.

Best Practices and Implementation:

Incorporate performance metrics in stability protocols:

For each time point (e.g., 0, 3, 6, 9, 12, 24 months), test:

• Delivered dose uniformity (DDU)
• Aerodynamic particle size distribution (APSD)
• Spray pattern and plume geometry (where applicable)
• Priming and tail-off performance

Store samples under ICH-recommended conditions (e.g., 25°C/60% RH, 30°C/75% RH) and evaluate any interaction between formulation and device materials (e.g., valve rubber, metal canisters).

Use validated equipment and trained operators:

Perform aerosol tests using calibrated cascade impactors (e.g., NGI), flow controllers, and dose collection apparatus. Operators must be trained in actuation technique, shaking, and sample handling to minimize variability. Ensure all tests follow approved SOPs aligned with regulatory guidance such as the FDA’s MDI/DPI draft guidance or EMA’s OINDP guideline.

Analyze and trend performance data across time points:

Use control charts and statistical trending to monitor:

• DDU within ±15% of labeled claim
• MMAD stability (within ±0.5 µm if specified)
• Consistent FPF and total emitted dose

Investigate any shift beyond control limits and document root cause assessments. Highlight these trends in the final stability summary and include supportive conclusions in CTD Module 3.2.P.8.3.

Inhalation products are only as effective as the aerosol they deliver. Ensuring consistent performance through stability testing not only protects patients—but also demonstrates product robustness, lifecycle control, and a scientifically sound regulatory strategy.